Table 1. Clinical characteristics of study population.
| All | Healthy | GINA 1–2 | GINA 3–5 | |
|---|---|---|---|---|
| Age (years) | 55.69±14.07 | 54.27±14.53 | 65.71±8.52 | 52.47±14.32 |
| Sex (M:F) | 15:20 | 5:6 | 3:4 | 7:10 |
| Body Mass Index | 26.87±4.67 | 28.34±4.73 | 25.74±5.25 | 26.39±4.45 |
| FEV1 Post BD | 2.83±1.08 | 3.58±1.02 | 2.19±0.66* | 2.61±1.02 |
| FEV1/FVC Post BD | 0.74±0.12 | 0.80±0.04 | 0.70±0.12 | 0.72±0.14 |
| FEV1% Predicted | 79.97±23.43 | 96.88±19.22 | 71.36±24.66 | 72.58±20.49* |
| FEV1/FVC% predicted | 95.06±14.41 | 102.03±5.25 | 91.75±16.40 | 91.92±16.57 |
Groups were compared with a Kruskal-Wallis test with post-hoc pairwise comparison performed using a Mann-Witney U-test with Bonferroni correction. Post bronchodilator FEV1 and FEV1% predicted were seen to have statistically significant relationships between the three patient groups.
* p < 0.01 compared with healthy control.